title: Use of abdominal radical trachelectomy to treat cervical cancer greater than 2 cm in diameter.
abstract: OBJECTIVE
  Invasive cervical cancer is one of the most common cancers, with 500,000 new cases diagnosed annually. Fertility preservation has become an important component of the overall quality of life of many cancer survivors. Expert opinion has suggested that fertility-sparing surgery should be limited to those patients diagnosed with cervical cancer less than 2 cm in diameter. Our objective was to report our abdominal radical trachelectomy (ART) experience in the opposite group of patients-those with a cervical cancer more than 2 cm in diameter.
  
  
  METHODS
  Between 1999 and 2006, a total of 45 patients with cervical carcinoma at International Federation of Gynecology and Obstetrics stage IB1-IB2 measuring more than 2 cm in diameter underwent fertility-sparing ART and pelvic lymphadenectomy at the 3 institutions where the authors are based (Budapest, Hungary; London, United Kingdom; New York, United States). They were followed up for more than 5 years.
  
  
  RESULTS
  For 69% of patients (n = 31), completed ART was considered to have been curative, and no adjuvant treatment was advised. Of those patients, 93.5% (n = 29) were alive at the time of follow-up. Thirty-one percent of patients (n = 14) underwent immediate completion of radical hysterectomy. Three of 8 patients who wished to fall pregnant delivered healthy neonates.
  
  
  CONCLUSIONS
  The 5-year survival rate (93.5%) for this case series is equal (or better) to rates reported in the literature for patient treated with radical hysterectomy. Our survival data seem to support the hypothesis that ART is a safe treatment option for patients with invasive cervical cancer lesions of more than 2 cm.
authors.affiliation: Department of Gynaecologic Oncology, St Stephen Hospital, Budapest, Hungary.
authors.forename: Balazs
authors.initials: B
authors.lastname: Lintner
authors.forename: Srdjan
authors.initials: S
authors.lastname: Saso
authors.forename: Laszlo
authors.initials: L
authors.lastname: Tarnai
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Novak
authors.forename: Laszlo
authors.initials: L
authors.lastname: Palfalvi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Del Priore
authors.forename: J Richard
authors.initials: JR
authors.lastname: Smith
authors.forename: Laszlo
authors.initials: L
authors.lastname: Ungar
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D002584:Cervix Uteri / Q000473:pathology / Q000601:surgery*; D005260:Female; D005298:Fertility; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011247:Pregnancy; D011379:Prognosis; D011446:Prospective Studies; D011788:Quality of Life; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*